GO:0090206 negative regulation of cholesterol metabolic process: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090206 describes any process that decreases the rate, frequency, or extent of cholesterol metabolism, the chemical reactions and pathways involving cholesterol, the principal sterol of vertebrates.
• Cholesterol metabolism is compartmentalized, and negative regulation occurs at multiple nodes including synthesis, uptake, esterification, efflux, and mitochondrial import.
• Key negative regulators include SCAP, HMGCR, SREBF2, NPC1, ABCA1, ABCG1, SOAT1, CYP7A1, and INSIG1/2, which together tune cholesterol availability.
• Dysregulated negative regulation of cholesterol metabolism contributes to cancer progression, immune escape, ferroptosis resistance, and metabolic disease.
• Nutrient and circadian inputs, such as glutamine availability and chrononutrition, can modulate cholesterol synthesis and its negative feedback.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to causally test negative regulators of cholesterol metabolism in disease contexts.
Description
GO:0090206, negative regulation of cholesterol metabolic process, is a Gene Ontology biological process term that captures any mechanism that decreases the rate, frequency, or extent of cholesterol metabolism. Cholesterol is the principal sterol of vertebrates and the precursor of bile acids and steroid hormones, so its levels must be tightly controlled to maintain membrane integrity, signaling, and systemic lipid homeostasis. Because cholesterol metabolism is a hub for metabolic, cardiovascular, and oncologic disease, understanding its negative regulation is a central goal for researchers in cell biology, immunology, and cancer biology. Experimental evidence shows that negative regulation is not a single switch but a layered network operating at transcription, post-translational modification, subcellular transport, and metabolite sensing. For example, mitochondrial cholesterol trafficking and redox biology intersect with disease phenotypes, while S-acylation of SCAP promotes cholesterol biosynthesis and tumor immune escape. This article synthesizes the authoritative GO definition with real PubMed literature to provide a research-grade overview of GO:0090206, its key genes, disease links, and the CRISPR-based methods used to study it.
negative regulation of cholesterol metabolic process At A Glance
| GO ID | GO:0090206 |
|---|---|
| GO term | negative regulation of cholesterol metabolic process |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency, or extent of cholesterol metabolism, including synthesis, uptake, esterification, transport, and catabolism |
| Definition source | QuickGO definition: Any process that decreases the rate, frequency, or extent of cholesterol metabolism, the chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones |
| Related processes | Cholesterol biosynthesis, cholesterol transport, bile acid synthesis, steroid hormone synthesis, mitochondrial cholesterol import |
| Cellular locations | Endoplasmic reticulum, plasma membrane, mitochondria, lysosome, lipid droplets |
| Disease relevance | Cancer, metabolic disease, immune escape, ferroptosis resistance, liver tumorigenesis |
What Is GO:0090206?
In practical terms, GO:0090206 refers to any biological process that reduces the rate, frequency, or extent of cholesterol metabolism, where cholesterol metabolism comprises the chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. This includes negative regulation of cholesterol synthesis, uptake, esterification, transport, and catabolism, as well as processes that lower the availability of cholesterol for metabolic conversions. The term is a biological process node, so it is used to annotate gene products that attenuate cholesterol metabolic flux rather than those that directly catalyze cholesterol reactions.
Why Is negative regulation of cholesterol metabolic process Important in Cell Biology?
Negative regulation of cholesterol metabolic process is important because cholesterol is essential for membrane function, lipid raft signaling, and steroid hormone synthesis, yet excess cholesterol is cytotoxic and contributes to atherosclerosis, neurodegeneration, and cancer. The same regulatory nodes that keep cholesterol in check can be hijacked by tumors to support proliferation, immune evasion, and metastasis. Understanding GO:0090206 therefore informs therapeutic strategies that target cholesterol synthesis, transport, and storage in cancer and metabolic disease.
• Maintains membrane cholesterol homeostasis and prevents lipotoxicity.
• Controls availability of cholesterol for bile acid and steroid hormone synthesis.
• Limits cholesterol accumulation in mitochondria, which affects redox biology and disease.
• Modulates immune responses by linking cholesterol transport to intestinal immunity.
• Supports ferroptosis sensitivity, and its dysregulation can increase tumorigenicity and metastasis.
• Regulates tumor immune escape through SCAP S-acylation and cholesterol biosynthesis.
• Connects nutrient sensing, such as glutamine availability, to cholesterol synthesis.
• Is influenced by circadian and nutritional inputs, as described in chrononutrition.
• Provides druggable nodes for cancer and metabolic disease.
• Requires causal validation using CRISPR knockout, point mutation, knock-in, and overexpression models.
What Happens During negative regulation of cholesterol metabolic process?
Transcriptional feedback control of cholesterol synthesis
In simple terms: When cells have enough cholesterol, they turn down the genes that make more cholesterol.
The SREBP pathway is a central negative feedback loop in cholesterol metabolism: when endoplasmic reticulum cholesterol rises, SCAP changes conformation and INSIG proteins retain the SCAP-SREBP complex, reducing SREBF2 processing and lowering expression of HMGCR and other synthesis genes. This transcriptional brake decreases the rate of cholesterol biosynthesis and is a defining component of GO:0090206.
Post-translational and transport-mediated attenuation
In simple terms: Even after proteins are made, cells can modify or move them to slow cholesterol production.
Negative regulation also occurs post-translationally. ZDHHC3-mediated S-acylation of SCAP promotes cholesterol biosynthesis and tumor immune escape, illustrating how a modification can override or tune negative regulation. Conversely, mitochondrial cholesterol transport and redox biology influence how much cholesterol is available for metabolism, and perturbations in these pathways alter disease phenotypes. Transport of cholesterol between compartments is therefore a key node where negative regulation is enforced.
Metabolite sensing and nutrient inputs
In simple terms: The cell senses nutrients like glutamine and adjusts cholesterol production accordingly.
Glutamine sensing licenses cholesterol synthesis, meaning nutrient availability can gate the pathway and its negative regulation. Chrononutrition studies further indicate that timing of nutrient intake influences cholesterol metabolism, linking circadian and nutritional cues to GO:0090206. These inputs allow cells to match cholesterol production with metabolic demand and avoid unnecessary flux.
Immune and tissue-level control
In simple terms: Cholesterol handling in immune cells affects how the body responds to diet and microbes.
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption, showing that negative regulation of cholesterol metabolism operates at the tissue and organism level. Dysregulated cholesterol homeostasis can also result in resistance to ferroptosis, increasing tumorigenicity and metastasis, which highlights the physiological consequences of losing negative regulation.
Key Genes Involved in GO:0090206 negative regulation of cholesterol metabolic process
The following genes and proteins are established participants in negative regulation of cholesterol metabolic process, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCAP | SREBP cleavage-activating protein; S-acylation promotes cholesterol biosynthesis | Target for tumor immune escape studies |
| INSIG1 | Retains SCAP-SREBP complex in ER to reduce cholesterol synthesis | Negative regulator of SREBP processing |
| INSIG2 | Retains SCAP-SREBP complex in ER to reduce cholesterol synthesis | Negative regulator of SREBP processing |
| SREBF2 | Transcription factor driving cholesterol synthesis genes | Central node of feedback control |
| HMGCR | Rate-limiting enzyme of cholesterol biosynthesis | Target of statins and negative regulation |
| NPC1 | Lysosomal cholesterol export; mutations cause cholesterol trafficking defects | Model for lysosomal cholesterol storage |
| ABCA1 | Cholesterol efflux to apoA-I; reduces cellular cholesterol | Negative regulator of cellular cholesterol |
| ABCG1 | Cholesterol efflux to HDL; reduces cellular cholesterol | Negative regulator of cellular cholesterol |
| SOAT1 | Esterifies cholesterol to cholesteryl esters for storage | Controls free cholesterol availability |
| CYP7A1 | Rate-limiting enzyme in bile acid synthesis from cholesterol | Links cholesterol catabolism to negative regulation |
| ZDHHC3 | S-acylates SCAP to promote cholesterol biosynthesis | Modifier of negative regulation in cancer |
| GLS | Glutamine sensing licenses cholesterol synthesis | Nutrient-dependent regulator |
| CD36 | Lipid uptake receptor influencing cholesterol availability | Immune-lipid crosstalk |
| ABCA1 in T cells | Cholesterol transport links intestinal immunity to dietary lipids | Tissue-level regulation |
| GPX4 | Ferroptosis regulator linked to cholesterol homeostasis | Dysregulated cholesterol increases ferroptosis resistance |
| ALKBH1 | tRNA N1-methyladenosine methylation drives liver tumorigenesis via cholesterol metabolism | Epitranscriptomic regulator |
| NR1H2 | Liver X receptor beta; promotes cholesterol efflux and negative regulation | Transcriptional control of efflux |
| NR1H3 | Liver X receptor alpha; promotes cholesterol efflux and negative regulation | Transcriptional control of efflux |
How Is negative regulation of cholesterol metabolic process Regulated?
Negative regulation of cholesterol metabolic process is controlled by a layered network. Transcriptional feedback via SREBF2 and INSIG1/2 reduces synthesis gene expression when cholesterol is abundant. Post-translational modification, such as ZDHHC3-mediated S-acylation of SCAP, can promote biosynthesis and tumor immune escape, effectively opposing negative regulation. Nutrient sensing, including glutamine availability, licenses cholesterol synthesis and can modulate the pathway. Circadian and nutritional timing, as studied in chrononutrition, further influences cholesterol metabolism. At the tissue level, T cell cholesterol transport connects intestinal immune responses to dietary lipid absorption, showing systemic regulation. Finally, dysregulated cholesterol homeostasis can result in ferroptosis resistance and increased tumorigenicity, indicating that negative regulation is critical for disease suppression.
negative regulation of cholesterol metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SCAP | Hepatocellular carcinoma immune escape | Knockout and point-mutation models in HCC cell lines |
| GPX4 | Ferroptosis resistance and metastasis | Overexpression and knockout in cancer cells |
| ALKBH1 | Liver tumourigenesis via cholesterol metabolism | Knockout and knock-in in liver cancer models |
| NPC1 | Lysosomal cholesterol trafficking disease | Point-mutation and knockout models |
| ABCA1 | Cholesterol efflux and cardiovascular risk | Overexpression and knockout models |
Cancer progression and metastasis
Dysregulated cholesterol homeostasis results in resistance to ferroptosis, increasing tumorigenicity and metastasis in cancer. ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma, linking negative regulation of cholesterol metabolism to immune evasion. N1-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism, providing an epitranscriptomic mechanism.
Metabolic and cardiovascular disease
Cholesterol is the precursor of bile acids and steroid hormones, and its excess contributes to metabolic and cardiovascular pathology. Mitochondrial cholesterol metabolism impacts redox biology and disease, and its dysregulation can alter cellular stress responses. Nutrient and circadian inputs, such as those described in chrononutrition, influence cholesterol handling and may modify disease risk.
Immune and intestinal biology
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption, showing that negative regulation of cholesterol metabolism affects mucosal immunity. Glutamine sensing licenses cholesterol synthesis, connecting nutrient availability to immune and metabolic cell states.
From negative regulation of cholesterol metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a negative regulator increase cholesterol synthesis? | CRISPR knockout of INSIG1/2 or SCAP |
| Does a disease-associated point mutation alter SCAP function? | Point-mutation knock-in |
| Can a tagged allele track SCAP localization? | Tagged knock-in |
| Does overexpression of ABCA1 reduce cellular cholesterol? | Overexpression model |
| Does glutamine sensing control cholesterol synthesis? | Knockout of GLS and metabolite rescue |
| Does tRNA methylation regulate cholesterol metabolism in liver cancer? | ALKBH1 knockout and knock-in |
How to Study the negative regulation of cholesterol metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Expression of cholesterol metabolic genes | Perturbation studies of negative regulators |
| Lipidomics | Cholesterol and cholesteryl ester levels | Quantifying flux changes |
| Radiolabeled flux assay | Rate of cholesterol synthesis and efflux | Functional validation of GO:0090206 |
| Fluorescence imaging | Subcellular cholesterol distribution | Tracking SCAP, NPC1, ABCA1 |
| Co-culture immune assay | T cell cholesterol transport and immune response | Intestinal immunity studies |
| Tumor immune escape assay | Immune recognition after SCAP modification | Cancer immunology |
| Epitranscriptomic profiling | tRNA methylation and cholesterol gene regulation | Liver tumorigenesis studies |
| Metabolite sensing assay | Glutamine-dependent cholesterol synthesis | Nutrient regulation studies |
Transcriptomic and epitranscriptomic profiling
RNA-seq and epitranscriptomic profiling can quantify expression of cholesterol synthesis and efflux genes after perturbation of negative regulators. These methods help identify how SCAP S-acylation or ALKBH1-dependent tRNA methylation reshapes cholesterol metabolic gene programs.
Lipidomics and cholesterol flux assays
Mass spectrometry-based lipidomics and radiolabeled cholesterol flux assays measure the rate of cholesterol synthesis, esterification, and efflux, directly reporting on GO:0090206 activity. These assays are essential to confirm that a candidate regulator decreases cholesterol metabolic flux.
Imaging and subcellular localization
Fluorescence imaging of tagged SCAP, NPC1, and ABCA1 allows researchers to track cholesterol transport between ER, lysosome, plasma membrane, and mitochondria. Mitochondrial cholesterol imaging is particularly relevant to redox biology and disease.
Immune and tissue-level functional assays
Co-culture and in vivo models can test how T cell cholesterol transport affects intestinal immunity and dietary lipid absorption. Tumor immune escape assays can measure how SCAP S-acylation alters immune recognition.
How CRISPR Can Be Used to Study GO:0090206 negative regulation of cholesterol metabolic process
Knockout
CRISPR knockout of negative regulators such as INSIG1, INSIG2, or ABCA1 can test whether loss of function increases cholesterol metabolic flux and alters disease phenotypes. Knockout of SCAP or ZDHHC3 can reveal effects on cholesterol biosynthesis and tumor immune escape.
Point Mutation
Point-mutation models can dissect specific residues required for SCAP S-acylation or NPC1 cholesterol transport, linking molecular lesions to GO:0090206 activity. These models are valuable when a disease-associated variant is suspected to alter negative regulation.
Knock-in
Knock-in of tagged alleles, such as fluorescently tagged SCAP or ABCA1, enables real-time tracking of protein localization and turnover during negative regulation of cholesterol metabolism. Knock-in of disease variants can model human cholesterol trafficking disorders.
Overexpression
Overexpression of negative regulators such as ABCA1, ABCG1, or INSIG1 can reduce cellular cholesterol and test whether enhancing GO:0090206 suppresses tumorigenic or metabolic phenotypes. Overexpression of SCAP or ZDHHC3 can conversely promote cholesterol biosynthesis and immune escape.
How EDITGENE Supports negative regulation of cholesterol metabolic process Research
Researchers studying negative regulation of cholesterol metabolic process-related genes often need to determine whether a candidate gene is causally involved in decreasing cholesterol metabolism or whether it is merely correlated with pathway activity. CRISPR-based models provide the causal evidence required to move from association to mechanism, and EDITGENE offers a full suite of services to generate and validate these models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cholesterol metabolic process research.
Frequently Asked Questions About negative regulation of cholesterol metabolic process
What is GO:0090206 negative regulation of cholesterol metabolic process?
GO:0090206 is a Gene Ontology biological process term describing any process that decreases the rate, frequency, or extent of cholesterol metabolism, the chemical reactions and pathways involving cholesterol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.
What genes are involved in negative regulation of cholesterol metabolic process?
Key genes include SCAP, INSIG1, INSIG2, SREBF2, HMGCR, NPC1, ABCA1, ABCG1, SOAT1, CYP7A1, ZDHHC3, GLS, and ALKBH1, based on published studies.
How does negative regulation of cholesterol metabolism work?
It works through transcriptional feedback via SREBF2 and INSIG1/2, post-translational modification such as SCAP S-acylation, nutrient sensing, and transport-mediated attenuation of cholesterol flux.
Why is negative regulation of cholesterol metabolism important in cancer?
Dysregulated cholesterol homeostasis can cause ferroptosis resistance and increased tumorigenicity and metastasis, while SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape.
What diseases are linked to GO:0090206?
Cancers such as hepatocellular carcinoma, metabolic and cardiovascular disease, and immune-related intestinal conditions have been linked to altered negative regulation of cholesterol metabolism.
How can CRISPR be used to study negative regulation of cholesterol metabolic process?
CRISPR knockout, point mutation, knock-in, and overexpression models can test whether a candidate gene causally decreases cholesterol metabolic flux and alters disease phenotypes.
What methods measure negative regulation of cholesterol metabolism?
RNA-seq, lipidomics, radiolabeled flux assays, fluorescence imaging, immune co-culture, and epitranscriptomic profiling are commonly used.
Is glutamine involved in cholesterol synthesis regulation?
Yes, glutamine sensing licenses cholesterol synthesis, linking nutrient availability to the pathway.
Does circadian timing affect cholesterol metabolism?
Chrononutrition studies indicate that timing of nutrient intake influences cholesterol metabolism.
What cell models are suitable for studying GO:0090206?
Knockout, point-mutation, knock-in, tagged knock-in, and overexpression cell models in cancer, liver, and immune cell backgrounds are suitable for causal studies.
Conclusion
GO:0090206 negative regulation of cholesterol metabolic process is a critical biological process that integrates transcriptional, post-translational, nutrient, and transport-level control of cholesterol metabolism. Its dysregulation is linked to cancer progression, immune escape, ferroptosis resistance, and metabolic disease, making it a high-value target for mechanistic and therapeutic research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with lipidomics, imaging, and screening, provide the causal evidence needed to advance this field.
References
- 1. Goicoechea L et al.. 2023. Mitochondrial cholesterol: Metabolism and impact on redox biology and disease.. Redox Biol 61:102643 PMID: 36857930
- 2. Gao Y et al.. 2025. T cell cholesterol transport links intestinal immune responses to dietary lipid absorption.. Science 390(6769):eadt4169 PMID: 41066556
- 3. Garcia BM et al.. 2024. Glutamine sensing licenses cholesterol synthesis.. EMBO J 43(23):5837-5856 PMID: 39433901
- 4. Liu W et al.. 2021. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer.. Nat Commun 12(1):5103 PMID: 34429409
- 5. Wu M et al.. 2024. ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma.. Cell Rep 43(11):114962 PMID: 39522165
- 6. Norum KR et al.. 1983. Transport of cholesterol.. Physiol Rev 63(4):1343-419 PMID: 6361811
- 7. Wang Y et al.. 2021. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism.. Nat Commun 12(1):6314 PMID: 34728628
- 8. Oda H. 2015. Chrononutrition.. J Nutr Sci Vitaminol (Tokyo) 61 Suppl:S92-4 PMID: 26598903
